Memorial Sloan Kettering Cancer Center

Cornell University

Susan Elizabeth Prockop

Richard John O'Reilly

Aisha Nasreen Hasan

Ekaterina Doubrovina

Guenther Koehne

Szilard Kiss

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

Methods of selecting T cell line and donor thereof for adoptive cellular therapy

Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof comprise administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Methods of treating CMV retinitis by T cell therapy

The invention relates to methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.

Methods of treating Epstein-Barr virus-associated lymphoproliferative disorders by T cell therapy

Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Growing community of inventors

New York, NY, United States of America

Susan Elizabeth Prockop